Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin’s lymphoma showed long-term progression-free survival benefits with first-line therapy with ...
Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been approved for relapsed and refractory Hodgkin’s lymphoma. We conducted an open-label, multicenter, randomized phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback